m6A Regulator and Potential Drug Response
General Information of the m6A Regulator (ID: REG00025)
| Regulator Name | YTH domain-containing family protein 3 (YTHDF3) | ||||
|---|---|---|---|---|---|
| Synonyms |
DF3
Click to Show/Hide
|
||||
| Gene Name | YTHDF3 | ||||
| Regulator Type | WRITER ERASER READER | ||||
| Regulator Link | Click to View Full Information of This Regulator | ||||
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Epidermal growth factor receptor (EGFR)
Afatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Afatinib. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Afatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [2] | ||
Cetuximab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cetuximab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Cetuximab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [3] | ||
Dacomitinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Dacomitinib. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Dacomitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [4] | ||
Epidermal growth factor [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Epidermal growth factor. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Epidermal growth factor through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [5] | ||
HEGF [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HEGF. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of HEGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [6] | ||
Icotinib hydrochloride [Registered]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Icotinib hydrochloride. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Icotinib hydrochloride through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [7] | ||
Lapatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Lapatinib. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Lapatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [8] | ||
Merimepodib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Merimepodib. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Merimepodib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [9] | ||
Necitumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Necitumumab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Necitumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [10] | ||
NERATINIB MALEATE [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for NERATINIB MALEATE. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of NERATINIB MALEATE through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [11] | ||
Nitroglycerin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Nitroglycerin. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Nitroglycerin through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [9] | ||
Panitumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Panitumumab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Panitumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [12] | ||
SKI-758 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SKI-758. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SKI-758 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
Vandetanib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Vandetanib. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Vandetanib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [14] | ||
AC0010 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AC0010. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AC0010 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [15] | ||
Almonertinib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Almonertinib. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Almonertinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [16] | ||
Amivantamab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Amivantamab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Amivantamab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [17] | ||
ASP1929 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ASP1929. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ASP1929 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [18] | ||
CO-1686 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CO-1686. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CO-1686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
DE-766 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for DE-766. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of DE-766 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [19] | ||
EGF816 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGF816. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of EGF816 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
HKI-272 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HKI-272. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of HKI-272 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [20] | ||
Indium-111 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Indium-111. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Indium-111 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [21] | ||
Rindopepimut [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Rindopepimut. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Rindopepimut through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [22] | ||
SYM-004 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYM-004. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SYM-004 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [23] | ||
Varlitinib [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Varlitinib. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Varlitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [24] | ||
Zalutumumab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Zalutumumab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Zalutumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [4] | ||
ABT-414 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ABT-414. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ABT-414 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [3] | ||
ABX-EGF [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ABX-EGF. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ABX-EGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [25] | ||
AFM24 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AFM24. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AFM24 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [26] | ||
ASP8273 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ASP8273. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ASP8273 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [27] | ||
BDTX-189 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BDTX-189. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BDTX-189 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [28] | ||
BMS-599626 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BMS-599626. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BMS-599626 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [2] | ||
BMS-690514 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BMS-690514. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BMS-690514 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [22] | ||
CART-EGFR [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CART-EGFR. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CART-EGFR through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [29] | ||
CetuGEX [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CetuGEX. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CetuGEX through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [30] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CI-1033. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CI-1033 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [31] | ||
CK-101 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CK-101. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CK-101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [31] | ||
Depatuxizumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Depatuxizumab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Depatuxizumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [31] | ||
EGFR antisense DNA [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR antisense DNA. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of EGFR antisense DNA through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [31] | ||
EGFR CART [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR CART. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of EGFR CART through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [32] | ||
EMB-01 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EMB-01. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of EMB-01 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [33] | ||
EMD 55900 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EMD 55900. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of EMD 55900 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [34] | ||
HER1-VSSP vaccine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HER1-VSSP vaccine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of HER1-VSSP vaccine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [35] | ||
HM-78136B [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HM-78136B. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of HM-78136B through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [36] | ||
Matuzumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Matuzumab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Matuzumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [37] | ||
MEHD-7945A [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MEHD-7945A. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of MEHD-7945A through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [38] | ||
Pelitinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Pelitinib. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Pelitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [39] | ||
RM-1929 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RM-1929. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of RM-1929 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [40] | ||
SN-32793 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SN-32793. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SN-32793 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [41] | ||
Sym013 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Sym013. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Sym013 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [42] | ||
Sym015 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Sym015. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Sym015 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [32] | ||
Tarloxotinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Tarloxotinib. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Tarloxotinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [43] | ||
TT-100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TT-100. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of TT-100 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [44] | ||
VATALANIB [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for VATALANIB. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of VATALANIB through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [21] | ||
ZN-e4 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ZN-e4. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ZN-e4 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [45] | ||
AMG 595 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AMG 595. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AMG 595 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [46] | ||
Anti-EGFR CAR T [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR CAR T. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Anti-EGFR CAR T through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [47] | ||
AP32788 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AP32788. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AP32788 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [48] | ||
AST-1306 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AST-1306. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AST-1306 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [21] | ||
BCA101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BCA101. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BCA101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [49] | ||
BIBX-1382 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BIBX-1382. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BIBX-1382 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [50] | ||
Cipatinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cipatinib. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Cipatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [51] | ||
CLN-081 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CLN-081. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CLN-081 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [52] | ||
CUDC-101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CUDC-101. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CUDC-101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [53] | ||
D2C7 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for D2C7. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of D2C7 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [54] | ||
EGFR806-specific CAR T cell [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR806-specific CAR T cell. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of EGFR806-specific CAR T cell through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [55] | ||
IMGN289 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for IMGN289. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of IMGN289 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
JNJ-26483327 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for JNJ-26483327. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of JNJ-26483327 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [56] | ||
LY3164530 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LY3164530. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of LY3164530 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [57] | ||
MCLA-158 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MCLA-158. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of MCLA-158 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [58] | ||
MM-151 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MM-151. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of MM-151 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [31] | ||
MR1-1 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MR1-1. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of MR1-1 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [59] | ||
PF-05230907 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PF-05230907. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PF-05230907 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [32] | ||
Pyrotinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Pyrotinib. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Pyrotinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [60] | ||
S-222611 [Phase 1b]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for S-222611. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of S-222611 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
SI-B001 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SI-B001. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SI-B001 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [61] | ||
SYN004 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYN004. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SYN004 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [32] | ||
111In-hEGF [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 111In-hEGF. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 111In-hEGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [62] | ||
(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [63] | ||
(3-Bromo-phenyl)-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (3-Bromo-phenyl)-quinazolin-4-yl-amine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of (3-Bromo-phenyl)-quinazolin-4-yl-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [64] | ||
(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [65] | ||
(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [63] | ||
10-hydroxy-18-methoxybetaenone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 10-hydroxy-18-methoxybetaenone. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 10-hydroxy-18-methoxybetaenone through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [63] | ||
2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [66] | ||
2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [67] | ||
2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [63] | ||
2-cyano-3-(3,4-dihydroxyphenyl)acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [63] | ||
2-methoxy-4-(2-nitrovinyl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-methoxy-4-(2-nitrovinyl)phenol. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 2-methoxy-4-(2-nitrovinyl)phenol through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [63] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [68] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [69] | ||
3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [70] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [71] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [72] | ||
3-Pyridin-4-yl-quinoline-6,7-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-Pyridin-4-yl-quinoline-6,7-diol. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 3-Pyridin-4-yl-quinoline-6,7-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [73] | ||
4-(2-nitroprop-1-enyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitroprop-1-enyl)benzene-1,2-diol. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4-(2-nitroprop-1-enyl)benzene-1,2-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [63] | ||
4-(2-nitrovinyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitrovinyl)benzene-1,2-diol. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4-(2-nitrovinyl)benzene-1,2-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [74] | ||
4-(2-nitrovinyl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitrovinyl)phenol. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4-(2-nitrovinyl)phenol through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [63] | ||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [75] | ||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [64] | ||
4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [63] | ||
4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [76] | ||
4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [77] | ||
4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [78] | ||
4557W [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4557W. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4557W through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [79] | ||
5,6-Bis-p-tolylamino-isoindole-1,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 5,6-Bis-p-tolylamino-isoindole-1,3-dione. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 5,6-Bis-p-tolylamino-isoindole-1,3-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [80] | ||
5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [81] | ||
6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [78] | ||
6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [78] | ||
6,7-diethoxy-4-styrylquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-styrylquinazoline. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 6,7-diethoxy-4-styrylquinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [78] | ||
6,7-dimethoxy-4-(2-phenylethynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [78] | ||
6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [78] | ||
6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [82] | ||
6,7-dimethoxy-N-m-tolylquinazolin-4-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-N-m-tolylquinazolin-4-amine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 6,7-dimethoxy-N-m-tolylquinazolin-4-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [71] | ||
6-chloro-N-(3-chlorophenyl)quinazolin-4-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [71] | ||
AFM-21 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AFM-21. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AFM-21 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
AG 112 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG 112. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AG 112 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [83] | ||
AG 9 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG 9. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AG 9 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
AG-213 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG-213. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AG-213 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [63] | ||
AG-538 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG-538. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AG-538 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [84] | ||
AG1478 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG1478. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AG1478 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [85] | ||
AGT-2000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AGT-2000. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AGT-2000 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
AL-6802 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AL-6802. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AL-6802 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
Anti-EGFR humanized mabs [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR humanized mabs. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Anti-EGFR humanized mabs through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
Anti-EGFR mab [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR mab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Anti-EGFR mab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
ARX-AHD [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ARX-AHD. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ARX-AHD through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [75] | ||
Benzyl-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Benzyl-quinazolin-4-yl-amine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Benzyl-quinazolin-4-yl-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [76] | ||
Bmab-200 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Bmab-200. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Bmab-200 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
BPIQ-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BPIQ-I. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BPIQ-I through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [86] | ||
CL-387785 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CL-387785. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CL-387785 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [77] | ||
Cochliobolic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cochliobolic acid. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Cochliobolic acid through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [87] | ||
EDP-13 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EDP-13. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of EDP-13 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
EGFR inhibitor [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR inhibitor. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of EGFR inhibitor through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [88] | ||
Epitinib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Epitinib. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Epitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
FHT-2107 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for FHT-2107. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of FHT-2107 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
GI-3000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for GI-3000. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of GI-3000 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
HDS-029 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HDS-029. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of HDS-029 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [89] | ||
HKI-9924129 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HKI-9924129. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of HKI-9924129 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [90] | ||
HM-61713B [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HM-61713B. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of HM-61713B through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
HTS-00213 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-00213. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of HTS-00213 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [71] | ||
HTS-02876 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-02876. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of HTS-02876 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [91] | ||
HTS-05058 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-05058. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of HTS-05058 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [68] | ||
ICR 62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ICR 62. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ICR 62 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [92] | ||
IPS-01003 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for IPS-01003. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of IPS-01003 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
LA22-radioimmunoconjugates [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LA22-radioimmunoconjugates. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of LA22-radioimmunoconjugates through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
LAVENDUSTIN A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LAVENDUSTIN A. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of LAVENDUSTIN A through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [78] | ||
mabionHER2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for mabionHER2. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of mabionHER2 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
MDP-01 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MDP-01. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of MDP-01 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
MG-111 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MG-111. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of MG-111 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [93] | ||
MT-062 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MT-062. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of MT-062 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [94] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [95] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [96] | ||
N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [84] | ||
N-(4-(phenylamino)quinazolin-6-yl)acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-(phenylamino)quinazolin-6-yl)acrylamide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N-(4-(phenylamino)quinazolin-6-yl)acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [92] | ||
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [66] | ||
N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [64] | ||
N4-(3-chlorophenyl)quinazoline-4,6-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N4-(3-chlorophenyl)quinazoline-4,6-diamine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N4-(3-chlorophenyl)quinazoline-4,6-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [94] | ||
N4-(3-methylphenyl)-4,6-quinazolinediamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N4-(3-methylphenyl)-4,6-quinazolinediamine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N4-(3-methylphenyl)-4,6-quinazolinediamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [68] | ||
NRC-2694 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for NRC-2694. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of NRC-2694 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
ON-128 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ON-128. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ON-128 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [64] | ||
OSI-75 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for OSI-75. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of OSI-75 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [97] | ||
PD-0166326 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-0166326. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PD-0166326 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [65] | ||
PD-0173956 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-0173956. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PD-0173956 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [65] | ||
PD-158780 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-158780. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PD-158780 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [64] | ||
PD-168393 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-168393. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PD-168393 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [96] | ||
PD182905 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD182905. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PD182905 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [41] | ||
PF 5208766 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PF 5208766. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PF 5208766 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [98] | ||
PP121 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PP121. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PP121 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [99] | ||
RG-50810 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RG-50810. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of RG-50810 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [91] | ||
RM-6427 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RM-6427. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of RM-6427 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
Ro-4396686 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Ro-4396686. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Ro-4396686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [68] | ||
RX-1792 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RX-1792. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of RX-1792 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
SYM-011 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYM-011. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SYM-011 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
TGF alpha [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TGF alpha. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of TGF alpha through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
Theliatinib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Theliatinib. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Theliatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [100] | ||
WHI-P154 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for WHI-P154. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of WHI-P154 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [82] | ||
WZ-3146 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for WZ-3146. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of WZ-3146 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [13] | ||
AZD-9935 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AZD-9935. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AZD-9935 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [101] | ||
AZD4769 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AZD4769. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AZD4769 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [2] | ||
CGP-52411 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CGP-52411. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CGP-52411 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [102] | ||
CGP-53353 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CGP-53353. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CGP-53353 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [41] | ||
Heparin-EGF-like factor [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Heparin-EGF-like factor. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Heparin-EGF-like factor through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [103] | ||
PD-153035 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-153035. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PD-153035 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [104] | ||
PKI166 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PKI166. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PKI166 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [105] | ||
RG7160 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RG7160. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of RG7160 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
TAK165 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TAK165. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of TAK165 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [107] | ||
Extracellular signal-regulated kinase 1 (ERK1)
ASTX029 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for ASTX029. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ASTX029 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [108], [109] | ||
BVD-523 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for BVD-523. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BVD-523 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [108], [110] | ||
HH2710 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for HH2710. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of HH2710 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [108], [111] | ||
ASN007 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for ASN007. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ASN007 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [108], [112] | ||
GDC-0994 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for GDC-0994. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of GDC-0994 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [31], [108] | ||
JSI-1187 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for JSI-1187. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of JSI-1187 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [108], [113] | ||
VAN-10-4-eluting stent [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for VAN-10-4-eluting stent. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of VAN-10-4-eluting stent through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [108], [114] | ||
COR-D [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for COR-D. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of COR-D through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [108], [115] | ||
6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for 6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [108], [116] | ||
Extracellular signal-regulated kinase 2 (ERK2)
ASTX029 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for ASTX029. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ASTX029 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [109] | ||
BVD-523 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for BVD-523. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BVD-523 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [117] | ||
HH2710 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for HH2710. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of HH2710 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [111] | ||
GDC-0994 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for GDC-0994. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of GDC-0994 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [31], [108] | ||
JSI-1187 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for JSI-1187. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of JSI-1187 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [113] | ||
LY3214996 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for LY3214996. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of LY3214996 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [112] | ||
VAN-10-4-eluting stent [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for VAN-10-4-eluting stent. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of VAN-10-4-eluting stent through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [114] | ||
COR-D [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for COR-D. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of COR-D through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [118] | ||
(4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for (4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of (4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [119] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [120] | ||
AEZS-131 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for AEZS-131. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AEZS-131 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [121] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Bisindolylmaleimide-I. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [122] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for BMS 536924. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BMS 536924 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [123] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for CI-1040. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CI-1040 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [124] | ||
DEBROMOHYMENIALDISINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for DEBROMOHYMENIALDISINE. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of DEBROMOHYMENIALDISINE through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [119] | ||
ERK inhibitor III [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for ERK inhibitor III. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ERK inhibitor III through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [125] | ||
FR-180204 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for FR-180204. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of FR-180204 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [126] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for KN-62. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of KN-62 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [127] | ||
KT-5720 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for KT-5720. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of KT-5720 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [125] | ||
Phosphonothreonine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Phosphonothreonine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Phosphonothreonine through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [128] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for RO-316233. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of RO-316233 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [119] | ||
Ro-4396686 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Ro-4396686. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Ro-4396686 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [119] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Ro31-8220. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Ro31-8220 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [72], [108] | ||
SCH772984 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for SCH772984. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SCH772984 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [129] | ||
SB220025 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for SB220025. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SB220025 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [108], [116] | ||
Forkhead box protein M1 (FOXM1)
(D-Arg)(9)-p19(ARF) 26-44 peptide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein M1 (FOXM1) is a therapeutic target for (D-Arg)(9)-p19(ARF) 26-44 peptide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of (D-Arg)(9)-p19(ARF) 26-44 peptide through regulating the expression of Forkhead box protein M1 (FOXM1). | [130], [131] | ||
Gap junction alpha-1 protein (GJA1)
Act1 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Gap junction alpha-1 protein (GJA1) is a therapeutic target for Act1. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Act1 through regulating the expression of Gap junction alpha-1 protein (GJA1). | [1], [132] | ||
Granexin gel [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Gap junction alpha-1 protein (GJA1) is a therapeutic target for Granexin gel. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Granexin gel through regulating the expression of Gap junction alpha-1 protein (GJA1). | [1], [133] | ||
HCB1019 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Gap junction alpha-1 protein (GJA1) is a therapeutic target for HCB1019. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of HCB1019 through regulating the expression of Gap junction alpha-1 protein (GJA1). | [1], [134] | ||
octanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Gap junction alpha-1 protein (GJA1) is a therapeutic target for octanol. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of octanol through regulating the expression of Gap junction alpha-1 protein (GJA1). | [1], [135] | ||
Interleukin-1 beta (IL1B)
Canakinumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Canakinumab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Canakinumab through regulating the expression of Interleukin-1 beta (IL1B). | [108], [136] | ||
Diacerein [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Diacerein. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Diacerein through regulating the expression of Interleukin-1 beta (IL1B). | [108], [137] | ||
Gallium nitrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Gallium nitrate. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Gallium nitrate through regulating the expression of Interleukin-1 beta (IL1B). | [108], [138] | ||
Glucosamine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Glucosamine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Glucosamine through regulating the expression of Interleukin-1 beta (IL1B). | [108], [139] | ||
Rilonacept [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Rilonacept. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Rilonacept through regulating the expression of Interleukin-1 beta (IL1B). | [108], [140] | ||
XOMA 052 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for XOMA 052. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of XOMA 052 through regulating the expression of Interleukin-1 beta (IL1B). | [108], [141] | ||
ABT-981 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for ABT-981. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ABT-981 through regulating the expression of Interleukin-1 beta (IL1B). | [108], [142] | ||
AC-201 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for AC-201. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AC-201 through regulating the expression of Interleukin-1 beta (IL1B). | [108], [143] | ||
LY-2189102 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for LY-2189102. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of LY-2189102 through regulating the expression of Interleukin-1 beta (IL1B). | [108], [144] | ||
CYT-013-IL1bQb [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for CYT-013-IL1bQb. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CYT-013-IL1bQb through regulating the expression of Interleukin-1 beta (IL1B). | [108], [145] | ||
TT-301 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for TT-301. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of TT-301 through regulating the expression of Interleukin-1 beta (IL1B). | [108], [146] | ||
Celastrol [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Celastrol. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Celastrol through regulating the expression of Interleukin-1 beta (IL1B). | [108], [147] | ||
DVD-Ig [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for DVD-Ig. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of DVD-Ig through regulating the expression of Interleukin-1 beta (IL1B). | [108], [148] | ||
CDP-484 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for CDP-484. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CDP-484 through regulating the expression of Interleukin-1 beta (IL1B). | [108], [149] | ||
Lysine-specific demethylase 5B (KDM5B)
PBIT [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Lysine-specific demethylase 5B (KDM5B) is a therapeutic target for PBIT. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PBIT through regulating the expression of Lysine-specific demethylase 5B (KDM5B). | [150], [151] | ||
RAC-alpha serine/threonine-protein kinase (AKT1)
AZD5363 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for AZD5363. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AZD5363 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [31], [108] | ||
Enzastaurin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Enzastaurin. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Enzastaurin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [152] | ||
GDC-0068 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GDC-0068. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of GDC-0068 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [31], [108] | ||
ARQ 092 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 092. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ARQ 092 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [153] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1033. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CI-1033 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [31], [108] | ||
CMX-2043 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CMX-2043. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CMX-2043 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [2], [108] | ||
GSK2110183 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GSK2110183. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of GSK2110183 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [154] | ||
PTX-200 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for PTX-200. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PTX-200 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [31], [108] | ||
RX-0201 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RX-0201. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of RX-0201 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [155] | ||
Triciribine prodrug [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Triciribine prodrug. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Triciribine prodrug through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [55], [108] | ||
ARQ 751 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 751. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ARQ 751 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [155] | ||
BMS-754807 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS-754807. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BMS-754807 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [156] | ||
M2698 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for M2698. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of M2698 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [31], [108] | ||
(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [119] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [120] | ||
4,5,6-trihydroxy-3-methylphthalide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6-trihydroxy-3-methylphthalide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4,5,6-trihydroxy-3-methylphthalide through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [119] | ||
A-443654 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-443654. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of A-443654 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [119] | ||
A-674563 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-674563. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of A-674563 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [157] | ||
Akt inhibitor VIII [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Akt inhibitor VIII. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Akt inhibitor VIII through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [125] | ||
ALM-301 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ALM-301. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ALM-301 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [158] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Bisindolylmaleimide-I. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [159] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [119] | ||
BX-517 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BX-517. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BX-517 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [127] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1040. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CI-1040 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [155] | ||
Inositol 1,3,4,5-Tetrakisphosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Inositol 1,3,4,5-Tetrakisphosphate. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Inositol 1,3,4,5-Tetrakisphosphate through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [160] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for KN-62. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of KN-62 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [159] | ||
Lactoquinomycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Lactoquinomycin. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Lactoquinomycin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [161] | ||
LD-101 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for LD-101. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of LD-101 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [155] | ||
MYRIOCIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for MYRIOCIN. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of MYRIOCIN through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [162] | ||
NU-1001-41 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for NU-1001-41. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of NU-1001-41 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [155] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RO-316233. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of RO-316233 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [119] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Ro31-8220. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Ro31-8220 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [163] | ||
SB-747651A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for SB-747651A. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SB-747651A through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [126] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for STAUROSPORINONE. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of STAUROSPORINONE through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [162] | ||
VLI-27 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for VLI-27. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of VLI-27 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [155] | ||
Squalestatin 1 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Squalestatin 1. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Squalestatin 1 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [31], [108] | ||
Stress-activated protein kinase 2a (p38 alpha)
Ozagrel [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Ozagrel. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Ozagrel through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [164] | ||
Losmapimod [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Losmapimod. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Losmapimod through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [165] | ||
Dilmapimod [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Dilmapimod. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Dilmapimod through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [166] | ||
VX-702 [Phase 2a]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for VX-702. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of VX-702 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [3], [108] | ||
VX-745 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for VX-745. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of VX-745 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [167] | ||
(5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for (5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of (5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [168] | ||
2-Chlorophenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 2-Chlorophenol. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 2-Chlorophenol through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [169] | ||
3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [125] | ||
3-(Benzyloxy)Pyridin-2-Amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 3-(Benzyloxy)Pyridin-2-Amine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 3-(Benzyloxy)Pyridin-2-Amine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [125] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [170] | ||
4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [171] | ||
4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [169] | ||
4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [123] | ||
6-(4-Fluoro-phenylsulfanyl)-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 6-(4-Fluoro-phenylsulfanyl)-9H-purine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 6-(4-Fluoro-phenylsulfanyl)-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [123] | ||
6-Benzylsulfanyl-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 6-Benzylsulfanyl-9H-purine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 6-Benzylsulfanyl-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [119] | ||
6-o-tolylquinazolin-2-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 6-o-tolylquinazolin-2-amine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 6-o-tolylquinazolin-2-amine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [172] | ||
6-Phenylsulfanyl-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 6-Phenylsulfanyl-9H-purine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 6-Phenylsulfanyl-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [123] | ||
9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [173] | ||
9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [123] | ||
9-Benzyl-6-phenylsulfanyl-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 9-Benzyl-6-phenylsulfanyl-9H-purine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 9-Benzyl-6-phenylsulfanyl-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [123] | ||
AG1478 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for AG1478. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AG1478 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [174] | ||
B-Octylglucoside [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for B-Octylglucoside. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of B-Octylglucoside through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [175] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Bisindolylmaleimide-I. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [123] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for CI-1040. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CI-1040 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [176] | ||
Dihydro-quinolinone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Dihydro-quinolinone. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Dihydro-quinolinone through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [177] | ||
DP-802 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for DP-802. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of DP-802 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [164] | ||
GSK-280 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for GSK-280. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of GSK-280 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [178] | ||
GW-788388 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for GW-788388. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of GW-788388 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [119] | ||
IN-1130 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for IN-1130. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of IN-1130 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [179] | ||
IN-1166 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for IN-1166. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of IN-1166 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [127] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for KN-62. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of KN-62 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [177] | ||
KT-5720 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for KT-5720. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of KT-5720 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [180] | ||
L-779450 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for L-779450. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of L-779450 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [120] | ||
ML-3163 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for ML-3163. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ML-3163 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [181] | ||
ML-3375 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for ML-3375. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ML-3375 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [182] | ||
ML-3403 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for ML-3403. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ML-3403 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [119] | ||
N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [183] | ||
N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [183] | ||
N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [183] | ||
N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [119] | ||
N-(4-methyl-benzyl)-4-phenoxy-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(4-methyl-benzyl)-4-phenoxy-benzamide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of N-(4-methyl-benzyl)-4-phenoxy-benzamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [184] | ||
Oxindole 94 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Oxindole 94. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Oxindole 94 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [183] | ||
PD-0166326 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for PD-0166326. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PD-0166326 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [185] | ||
PD-0173956 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for PD-0173956. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PD-0173956 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [172] | ||
PHA-666859 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for PHA-666859. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PHA-666859 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [164] | ||
Phenyl-(3-phenyl-1H-indazol-6-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Phenyl-(3-phenyl-1H-indazol-6-yl)-amine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Phenyl-(3-phenyl-1H-indazol-6-yl)-amine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [119] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for RO-316233. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of RO-316233 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [123] | ||
Ro-3201195 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Ro-3201195. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Ro-3201195 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [186] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Ro31-8220. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Ro31-8220 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [185] | ||
RWJ-68354 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for RWJ-68354. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of RWJ-68354 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [181] | ||
SB-216995 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB-216995. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SB-216995 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [187] | ||
SB-218655 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB-218655. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SB-218655 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [172] | ||
SB-227931 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB-227931. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SB-227931 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [188] | ||
Small molecule 34 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Small molecule 34. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Small molecule 34 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [125] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for STAUROSPORINONE. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of STAUROSPORINONE through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [119] | ||
Talmapimod [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Talmapimod. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Talmapimod through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [169] | ||
Triazolopyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Triazolopyridine. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Triazolopyridine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [169] | ||
UCB-1277763 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for UCB-1277763. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of UCB-1277763 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [164] | ||
ZM-336372 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for ZM-336372. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ZM-336372 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [189] | ||
FR167653 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for FR167653. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of FR167653 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [3], [108] | ||
PAMAPIMOD [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for PAMAPIMOD. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PAMAPIMOD through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [3], [108] | ||
R-1487 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for R-1487. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of R-1487 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [166] | ||
SB 203580 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB 203580. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SB 203580 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [190] | ||
SB 235699 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB 235699. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SB 235699 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [191] | ||
SB-242235 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB-242235. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SB-242235 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [192] | ||
SB220025 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB220025. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SB220025 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [193] | ||
SC-102 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SC-102. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of SC-102 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [108], [125] | ||
Tumor necrosis factor (TNF)
Adalimumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Adalimumab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Adalimumab through regulating the expression of Tumor necrosis factor (TNF). | [108], [194] | ||
Certolizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Certolizumab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Certolizumab through regulating the expression of Tumor necrosis factor (TNF). | [108], [195] | ||
Enbrel [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Enbrel. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Enbrel through regulating the expression of Tumor necrosis factor (TNF). | [108], [196] | ||
Etanercept [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Etanercept. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Etanercept through regulating the expression of Tumor necrosis factor (TNF). | [108], [197] | ||
Golimumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Golimumab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Golimumab through regulating the expression of Tumor necrosis factor (TNF). | [108], [198] | ||
Infliximab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Infliximab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Infliximab through regulating the expression of Tumor necrosis factor (TNF). | [108], [199] | ||
Lenalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Lenalidomide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Lenalidomide through regulating the expression of Tumor necrosis factor (TNF). | [108], [139] | ||
Nafamostat [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Nafamostat. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Nafamostat through regulating the expression of Tumor necrosis factor (TNF). | [108], [200] | ||
Pentoxifylline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Pentoxifylline. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Pentoxifylline through regulating the expression of Tumor necrosis factor (TNF). | [108], [201] | ||
Thalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Thalidomide. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Thalidomide through regulating the expression of Tumor necrosis factor (TNF). | [108], [202] | ||
ABP 501 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABP 501. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ABP 501 through regulating the expression of Tumor necrosis factor (TNF). | [108], [203] | ||
CPL-7075 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CPL-7075. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CPL-7075 through regulating the expression of Tumor necrosis factor (TNF). | [108], [204] | ||
Golnerminogene pradenovac [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Golnerminogene pradenovac. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Golnerminogene pradenovac through regulating the expression of Tumor necrosis factor (TNF). | [108], [205] | ||
PF-06410293 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-06410293. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PF-06410293 through regulating the expression of Tumor necrosis factor (TNF). | [108], [206] | ||
PF-06438179 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-06438179. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PF-06438179 through regulating the expression of Tumor necrosis factor (TNF). | [108], [207] | ||
ABT-122 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABT-122. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ABT-122 through regulating the expression of Tumor necrosis factor (TNF). | [108], [208] | ||
AN0128 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AN0128. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AN0128 through regulating the expression of Tumor necrosis factor (TNF). | [108], [209] | ||
AP-301-IH [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AP-301-IH. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AP-301-IH through regulating the expression of Tumor necrosis factor (TNF). | [108], [210] | ||
ART621 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ART621. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ART621 through regulating the expression of Tumor necrosis factor (TNF). | [53], [108] | ||
BAICALEIN [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for BAICALEIN. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BAICALEIN through regulating the expression of Tumor necrosis factor (TNF). | [108], [211] | ||
COVA322 [Phase 1/2a]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for COVA322. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of COVA322 through regulating the expression of Tumor necrosis factor (TNF). | [108], [212] | ||
DLX-105 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for DLX-105. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of DLX-105 through regulating the expression of Tumor necrosis factor (TNF). | [108], [213] | ||
ESBA-105 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ESBA-105. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ESBA-105 through regulating the expression of Tumor necrosis factor (TNF). | [108], [214] | ||
Ortataxel [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Ortataxel. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Ortataxel through regulating the expression of Tumor necrosis factor (TNF). | [108], [215] | ||
Pegsunercept [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Pegsunercept. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Pegsunercept through regulating the expression of Tumor necrosis factor (TNF). | [108], [216] | ||
RDP58 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for RDP58. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of RDP58 through regulating the expression of Tumor necrosis factor (TNF). | [108], [217] | ||
TNF alpha kinoid [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for TNF alpha kinoid. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of TNF alpha kinoid through regulating the expression of Tumor necrosis factor (TNF). | [108], [218] | ||
ABBV-257 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABBV-257. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ABBV-257 through regulating the expression of Tumor necrosis factor (TNF). | [108], [219] | ||
AST-005 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AST-005. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AST-005 through regulating the expression of Tumor necrosis factor (TNF). | [108], [220] | ||
AVX-470 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AVX-470. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AVX-470 through regulating the expression of Tumor necrosis factor (TNF). | [108], [220] | ||
CYT-609 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CYT-609. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CYT-609 through regulating the expression of Tumor necrosis factor (TNF). | [108], [221] | ||
INB03 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for INB03. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of INB03 through regulating the expression of Tumor necrosis factor (TNF). | [108], [222] | ||
PF-05230905 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-05230905. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PF-05230905 through regulating the expression of Tumor necrosis factor (TNF). | [108], [223] | ||
PMI-005 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PMI-005. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PMI-005 through regulating the expression of Tumor necrosis factor (TNF). | [108], [224] | ||
ABX-0401 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABX-0401. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ABX-0401 through regulating the expression of Tumor necrosis factor (TNF). | [108], [148] | ||
Celastrol [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Celastrol. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Celastrol through regulating the expression of Tumor necrosis factor (TNF). | [21], [108] | ||
2-Propanol, Isopropanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for 2-Propanol, Isopropanol. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 2-Propanol, Isopropanol through regulating the expression of Tumor necrosis factor (TNF). | [108], [225] | ||
DOM-0215 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for DOM-0215. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of DOM-0215 through regulating the expression of Tumor necrosis factor (TNF). | [108], [226] | ||
IK-862 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for IK-862. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of IK-862 through regulating the expression of Tumor necrosis factor (TNF). | [108], [227] | ||
PKF-241-466 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PKF-241-466. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PKF-241-466 through regulating the expression of Tumor necrosis factor (TNF). | [108], [227] | ||
PKF-242-484 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PKF-242-484. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PKF-242-484 through regulating the expression of Tumor necrosis factor (TNF). | [108], [228] | ||
Y-39041 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Y-39041. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Y-39041 through regulating the expression of Tumor necrosis factor (TNF). | [108], [229] | ||
ALS-00T2-0501 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ALS-00T2-0501. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ALS-00T2-0501 through regulating the expression of Tumor necrosis factor (TNF). | [108], [230] | ||
AME-527 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AME-527. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of AME-527 through regulating the expression of Tumor necrosis factor (TNF). | [108], [226] | ||
Camobucol [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Camobucol. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Camobucol through regulating the expression of Tumor necrosis factor (TNF). | [108], [231] | ||
CDP571 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CDP571. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CDP571 through regulating the expression of Tumor necrosis factor (TNF). | [108], [232] | ||
CRx-191 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CRx-191. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CRx-191 through regulating the expression of Tumor necrosis factor (TNF). | [108], [233] | ||
CYT-007-TNFQb [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CYT-007-TNFQb. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CYT-007-TNFQb through regulating the expression of Tumor necrosis factor (TNF). | [108], [234] | ||
FR-133605 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for FR-133605. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of FR-133605 through regulating the expression of Tumor necrosis factor (TNF). | [108], [235] | ||
ISIS 104838 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ISIS 104838. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of ISIS 104838 through regulating the expression of Tumor necrosis factor (TNF). | [108], [236] | ||
MDL-201112 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for MDL-201112. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of MDL-201112 through regulating the expression of Tumor necrosis factor (TNF). | [108], [237] | ||
PNU-282987 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PNU-282987. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of PNU-282987 through regulating the expression of Tumor necrosis factor (TNF). | [108], [238] | ||
Segard [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Segard. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Segard through regulating the expression of Tumor necrosis factor (TNF). | [108], [239] | ||
TNFQb therapeutic vaccines [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for TNFQb therapeutic vaccines. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of TNFQb therapeutic vaccines through regulating the expression of Tumor necrosis factor (TNF). | [108], [240] | ||
References